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Abstract: The antigen-specific Th17 responses in the lungs for improved immunity against
Mycobacterium tuberculosis (Mtb) infection are incompletely understood. Tuberculosis (TB) vaccine
candidate HSP90-ESAT-6 (E6), given as a Bacillus Calmette-Guérin (BCG)-prime boost regimen,
confers superior long-term protection against the hypervirulent Mtb HN878 infection, compared to
BCG or BCG-E6. Taking advantage of protective efficacy lead-out, we found that ESAT-6-specific
multifunctional CD4+IFN-γ+IL-17+ T-cells optimally correlated with protection level against Mtb
infection both pre-and post-challenge. Macrophages treated with the supernatant of re-stimulated
lung cells from HSP90-E6-immunised mice significantly restricted Mtb growth, and this phenomenon
was abrogated by neutralising anti-IFN-γ and/or anti-IL-17 antibodies. We identified a previously
unrecognised role for IFN-γ/IL-17 synergism in linking anti-mycobacterial phagosomal activity to
enhance host control against Mtb infection. The implications of our findings highlight the fundamental
rationale for why and how Th17 responses are essential in the control of Mtb, and for the development
of novel anti-TB subunit vaccines.
Keywords: Mycobacterium tuberculosis; BCG-prime boost; IFN-γ/IL-17; multifunctional T cells;
phagosome maturation
1. Introduction
Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (Mtb), is associated
with high morbidity and mortality, thus posing a global public health problem. In 2017, TB ranked as
one of the top ten causes of death, with an estimated 10 million new cases and 1.6 million deaths [1]. In
addition, approximately 1.7 billion people, 23% of the global population, are estimated to have latent
TB infection and to be at risk of developing active TB during their lifetime. In addition, the emergence
of Mtb strains resistant to TB drugs poses a major growing burden of hard-to-treat infections [2].
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) currently is the only licensed prophylactic
vaccine; however, it provides insufficient protection against TB, and thus, novel effective vaccines are
urgently needed [3]. Various types of adjuvants, antigen (Ag) targets, and vaccine platforms have been
developed in an aim to improve Mtb vaccines. These efforts have yielded various results, with some
producing positive outcomes in clinical trials. Heterologous prime-boost regimens involving priming
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with BCG, followed by an adjuvant boost, are a promising vaccination strategy against TB [4], and
have a proven high level of efficacy.
Clinical efficacy trials of three TB multi-antigenic subunit vaccines (H4:IC31, M72/AS01E, and
ID93) conducted in 2018 yielded encouraging results, and helped to advance experimental design
strategies in the field of TB vaccine development [5–7]. All three subunit vaccine candidates are
multi-antigen, single-fusion protein vaccines formulated with their own unique adjuvant, and have
been evaluated in BCG-vaccinated healthy populations in TB-endemic regions, mainly in South-African
countries. The candidates effectively boosted a BCG-induced immune response and provided long-term
protection and induced persistent Th1-biased multifunctional CD4+ T-cell responses in preclinical TB
models [8,9].
We previously demonstrated that a subunit vaccine consisting of the ESAT-6 Mtb antigen fused
with HSP90 (hereafter referred to as HSP90-E6) formulated with MPL/dimethyldioctadecyl- ammonium
(DDA) as an adjuvant confers high-level, robust protection against the hypervirulent Beijing strain,
HN878 [10]. The improved protection provided by this vaccine was characterised by durable, robust
pulmonary Th1-polarised multifunctional CD4+ T-cell immune responses in the lungs in comparison
with BCG or ESAT-6 alone in a standard mouse model [10]. These findings suggested the potential
usability of this vaccine candidate.
Similar to MPL, CIA05 is a TLR4 agonist purified from an Escherichia coli strain that expresses
lipopolysaccharides with short carbohydrate chains and detoxified by alkaline hydrolysis [11]. CIA05
stimulates the secretion of various cytokines and chemokines from human monocytes and mouse
bone-marrow dendritic cells (DCs), and the immuno-stimulatory activity of CIA05 is higher than that
of MPL [11]. Therefore, in the current study, we tested the efficacy of HSP90-E6 TB vaccine with CIA05
instead of MPL adjuvant.
For a vaccine to induce protection against TB, antigen-specific T-cells should be rapidly recruited
to the lungs and activate the infected phagocytes [12,13]. While CD4+IFN-γ+ T-cells are generally
thought to be essential for Mtb control [14,15], IFN-γ production does not correlate with protection
against TB [16–18]. Moreover, recent data suggest that CD4+ T-cells producing multiple cytokines,
including IFN-γ, TNF-α, and IL-2, are associated with protection against TB [19–22], suggesting that
multifunctional CD4+ T-cells are important in Mtb control. Further, IL-17 and Th17 responses have
been found to be important for protective immunity against TB [13,23–29]. CD4+IL-17+ T-cells play
a particularly crucial role in vaccine-mediated immunity [13,30] by promoting a prompt recruitment of
CD4+IFN-γ + T-cells to the lungs, leading to early control of Mtb replication in Mtb-infected mice [13].
However, the function of IL-17 in the protection against Mtb and, in particular, in synergism with
IFN-γ in Mtb-infected macrophages, remains unclear. Our previous study investigating cytokine
profiles from DCs activated by E6-HSP90 treatment and co-cultured with naïve CD4+ T-cells suggested
a possible involvement of the Th17 response [10]; however, whether the protective mechanism of this
vaccine candidate is associated with its Th17-inducing capacity remained to be clarified.
In the current study, a heterologous prime-boost regimen with HSP90-E6/CIA05 following BCG
vaccination was used to evaluate putative correlations between protective efficacy and CD4+ T-cell
subset phenotypes. In addition, we investigated whether a Th17 response is required for the optimal
efficacy of this vaccine candidate, as well as the underlying mechanism.
2. Materials and Methods
2.1. Ethics Statement
All animal studies were performed in accordance with Korean Food and Drug Administration
(KFDA) guidelines. The experimental protocols used in this study were reviewed and approved by
the Ethics Committee and Institutional Animal Care and Use Committee (Permit Number: 2014-0197-3)
of the Laboratory Animal Research Center at Yonsei University College of Medicine (Seoul, Korea) and
IACUC (CNU-00284) of animal care at Chungnam National University (Daejeon, Korea).
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2.2. Mice
Specific pathogen-free female C57BL/6J mice (6–7 weeks old) were purchased from Japan SLC,
Inc. (Shizuoka, Japan), and maintained under barrier conditions in the ABSL-3 facility at the Yonsei
University College of Medicine with constant temperature (24 ◦C ± 1 ◦C) and humidity (50% ±
5%). The animals were fed a sterile commercial mouse diet with ad libitum access to water under
standardized light-controlled conditions (12-h light and 12-h dark periods). The mice were monitored
daily, and none of the mice showed any clinical symptoms or illness during this experiment.
2.3. Preparations of Mtb Strains and Antigens
Mtb HN878 was obtained from the strain collections of the International Tuberculosis Research
Center (ITRC, Changwon, Gyeongsangnam-do, South Korea). BCG (Pasteur strain 1173P2) was kindly
provided by Dr. Brosch, from the Pasteur Institute (Paris, France). All mycobacteria used in this study
were prepared as described previously [31].
PPD was kindly provided by Dr. Michael Brennan at Aeras (Rockville, MD, USA). To
produce a recombinant HSP90-E6 protein, the corresponding gene was amplified by PCR using
Mtb H37Rv ATCC27294 genomic DNA as a template and the following primers: HSP90 forward,
5′- CATATGAACGCCCATGTCGAGCAGTTG-3′, and reverse, 5′-GAATTCGGCAAGGTACGCGCG
AGACGTTC-3′; ESAT-6 forward, 5′-AAGCTTATGACAGAGCAGCAGTGGAAT-3′, and reverse,
5′-CTCGAGTGCGAACATCCCAGTGACGTT-3′. The PCR product of HSP90 was digested with
NdeI and EcoRI, and ESAT-6 was cut with HindIII and XhoI. The products were inserted into
the pET22b (+) vector (Novagen, Madison, WI, USA), and the resultant plasmids were sequenced.
The recombinant plasmids were transfected into E. coli BL21 cells by heat-shock for 1 min at 42 ◦C.
To produce a recombinant fusion protein, the PCR products of HSP90 were inserted into previously
produced ESAT-6-containing pET22b (+) vector. The recombinant protein was prepared as previously
described [10].
2.4. Immunisation and Mtb Infection in Mice
C57BL/6 mice (n = 12/group) were injected subcutaneously with a single dose of 2 × 105 colony
forming units (CFU) of BCG Pasteur 1173P2 (prime), and were immunised 3 months later, through 3
intramuscular injections administered 3 weeks apart (boosts). Each immunisation contained 2 µg of
ESAT-6 and HSP90-E6 with 2 µg of CIA05 formulated in 250 µg of dimethyldioctadecylammonium
(DDA) liposomes. The control group was immunised with CIA05/DDA only. Immunogenicity was
analysed in spleen and lung cells 4 weeks after the last immunisation. Afterwards, immunised mice
(CIA05/DDA, BCG, BCG+ESAT-6/CIA05/DDA, and BCG+HSP90-E6/CIA05/DDA) were challenged by
aerosol exposure with Mtb HN878 strain, as previously described [32]. Briefly, mice were exposed
to HN878 strain in the calibrated inhalation chamber of an airborne infection apparatus for 60 min,
delivering a predetermined dose (Glas-Col, Terre Haute, IN, USA); approximately 200 viable bacteria
were delivered.
2.5. Intracellular Cytokine Staining
After 10 wk Mtb HN878 challenge, the mice were euthanized by CO2 asphyxiation, and
single cell suspensions (1 × 106 cells) from immunised and infected mice were stimulated with
PPD (2 µg/mL) or ESAT-6 (2 µg/mL) at 37 ◦C for 12 h in the presence of both GolgiPlug and
GolgiStop (BD Biosciences, San Jose, CA, USA). PBS-washed cells were blocked with anti-CD16/32
(BD Biosciences) at 4 ◦C for 20 min. After that, cells were surface stained with Brilliant Violet
(BV) 605-conjugated anti-CD90.2, peridinin chlorophyll (PerCP)-Cy5.5-conjugated anti-CD4 (BD
Biosciences), allophycocyanin (APC)-Cy7-conjugated anti-CD8 (Biolegend, San Diego, CA, USA),
and V450-conjugated anti-CD44 antibodies at 4 ◦C for 30 min, and were washed three times with
PBS. These cells were fixed and permeabilised with the Cytofix/Cytoperm kit (BD Biosciences)
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at 4 ◦C for 30 min. Then, cells were washed three times with Perm/Wash (BD Biosciences) and
stained intracellularly with PE-conjugated anti-IFN-γ, PE-Cy7-conjugated anti-IL-2, APC-conjugated
anti-TNF-α and Alexa488-conjugated anti-IL-17 (T-bet, GATA-3 and RORγt) (BD Biosciences) at 4 ◦C
for 30 min. After being washed three times with Perm/Wash, cells were fixed using IC Fixation buffer
(eBioscience). Then, PBS-resuspended cells were analysed on a CytoFLEX S Flow cytometer (Beckman
Coulter, Indianapolis, IN, USA), using the commercially available software program FlowJo (Treestar,
Inc., San Carlos, CA).
2.6. Bacterial Counts and Histopathological Analysis
Adherent bone marrow-derived macrophages (BMDMs) (2 × 105 cells/well) were washed twice
in PBS and infected, in triplicate with Mtb (2 × 105 bacilli/well). Tubercle bacilli and macrophages
were incubated for 4 hr. Then, the infected BMDMs were treated with amikacin (200 µg/mL) for 2 hr.
After 2 hr, monolayers were washed to remove extracellular bacilli, and this time point was considered
as day 0. Two different types of measurement of CFU in infected macrophages were used. First,
the infected BMDMs were preincubated with neutralizing antibody against IFN-γR1 (R&D Systems,
Minneapolis, MN, USA) (200 ng/mL), IL-17RA (R&D Systems) (200 ng/mL), or IFN-γR1/IL-17RA
(200 ng/mL) for 2 hr, and then a previously prepared culture supernatants—antigen-activated DCs
co-cultured with CD4+ T-cells at a DC:T-cell ratio of 1:10 for 3 days—was added to each well, and
the plate was incubated for 3 days. The following DC-activating antigens were used: PPD, ESAT-6,
and HSP90-E6 (2 µg/mL). Second, infected BMDMs were treated with recombinant mIFN-γ (R&D
Systems) (10 ng/mL), recombinant mIL-17 (R&D Systems) (10 ng/mL), or recombinant mIFN-γ/mIL-17
(1 ng/mL) for 3 days. The number of ingested and internalised Mtb by the BMDMs was calculated
by lysing the infected cells from one of the wells in distilled water. The Tubercle bacilli counts in
the inoculum were then checked by serial dilution and plating on 7H10 agar with 10% Middlebrook
OADC supplement (Difco, Detroit, MI). The plates were incubated at 37 ◦C for 3 weeks. Afterwards,
the plates were taken out, and colony forming units (CFUs) were calculated based on the number of
colonies of Mtb.
Ten weeks after Mtb HN878 infection, the lungs and spleens dissected from the infected mice
were homogenised. The number of viable bacteria was determined by plating serial dilutions of
the organ (left lung or half spleen) homogenates onto Middlebrook 7H11 agar (Difco Laboratories,
Detroit, MI, USA) supplemented with 10% OADC (Difco Laboratories), amphotericin B (Sigma-Aldrich,
St. Louis, MO, USA), and 2 µg/mL 2-thiophenecarboxylic acid hydrazide (Sigma-Aldrich). Colonies
were counted after 4 weeks of incubation at 37 ◦C. For the histopathological analysis, the superior
lobes of the right lung were vertically or horizontally sectioned, and stained with Haemotoxylin and
Eosin (H&E). For assessment of severity of inflammation, representative horizontal sections were used.
The level of inflammation and the size of lesions in the lungs was evaluated using the ImageJ software
(National Institutes of Health, Bethesda, MD), as described previously [32].
2.7. Quantification of Cytokines
A sandwich enzyme-linked immunosorbent assay (ELISA) was used for detecting IL-1β,
TNF-α, IFN-γ, IL-4, IL-2, IL-12p70, IL-12p19, IL-17, and IL-10 in culture supernatants, as described
previously [10]. Cytokines present in supernatants obtained from in vitro culture and in ex vivo
single cells isolated from the lungs, spleens and lymph nodes of immunised or Mtb-infected mice
were measured using commercial ELISA kits as per the manufacturers’ instructions after stimulation
with the PPD, ESAT-6, and HSP90-E6 (2 µg/mL). PPD was kindly provided by Dr. Brennan, at Aeras
(Rockville, MD, USA). All ELISA kits were purchased from eBioscience, except for the IL-10 ELISA kit
(BD Bioscience).
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2.8. Cell Culture
Murine bone marrow-derived DCs were generated, cultured, and purified, as described in
a previous study [10]. BMDMs were prepared using recombinant M-CSF, as previously described [10].
Briefly, bone marrow cells isolated from C57BL/6 mice were lysed with red blood cell (RBC)-lysing buffer
(ammonium chloride 4.15 g/500 mL, 0.01 M Tris-HCl buffer pH 7.5 ± 0.2) and washed with the RPMI
1640 medium. The obtained cells were plated in six-well culture plates (106 cells/mL, 3 mL/well) and
cultured at 37 ◦C in the presence of 5% CO2 in RPMI 1640 media supplemented with 100 unit/mL
penicillin/streptomycin (Lonza), 10% of fetal bovine serum (Lonza), 50 µM mercaptoethanol (Lonza),
0.1 mM nonessential amino acids (Lonza), 1 mM sodium pyruvate (Sigma), 20 ng/mL GM-CSF, and
10 ng/mL IL-4 (BMDCs) or 20 ng/mL M-CSF (BMDMs).
2.9. In Vitro T-Cell Proliferation and Polarisation Assay
CD4+ T cells were purified by CD4+ T Cell Isolation Kit using a LS column (Miltenyi Biotec) from
total mononuclear cells extracted from individually vaccinated C57BL/6J mice. These T-cells were
stained with 1 µM CFSE (Invitrogen) as previously described [33]. DCs (2 × 105 cells per well) treated
with 2 µg/mL of PPD, E6, or HSP90-E6 for 24 hr were co-cultured with CFSE-stained and CD4+ T-cells
(2 × 106) at DC:T-cell ratios of 1:10. On day 3 or 4 of co-culture, each T-cell batch was stained with anti
CD4+, T-bet, or RORγt mAbs, and analysed by flow cytometry.
2.10. Colocalisation of Phagosomes and Phagolysosomes
To observe the colocalisation of Mtb-containing phagosomes, we performed confocal microscopy
as described previously [34]. Macrophages (2 × 105/well) were prepared in 12-well culture dishes
that contained 18 mm diameter round glass coverslips. The cells were then infected with Mtb-RFP
at an MOI of 1 for 4 h at 37 ◦C in a 5% CO2 incubator and incubated with (i) recombinant mIFN-γ
(1 ng/mL), recombinant mIL-17 (1 ng/mL), or recombinant mIFN-γ/mIL-17 (1 ng/mL), (ii) re-stimulated
with ESAT-6 in vaccinated-lung cells with/without IFN-γR1 (200 ng/mL), IL-17RA (200 ng/mL), or
IFN-γR1/IL-17RA (200 ng/mL). After 72 hr incubation, the cells were stained with anti-LAMP1 (Santa
Cruz, CA, USA) and imaged under a confocal microscope.
2.11. Statistical Analysis
All the experiments were repeated at least three times with consistent results. For immunological
analysis, the levels of significance for comparison between samples were determined by Tukey’s
multiple comparison or unpaired t-test. For CFU and histopathology analysis, Mann-Whitney rank
test was used when comparing the differences between two different groups. For statistical analysis,
GraphPad Prism version 6.00 for Windows was used (GraphPad Software, La Jolla California USA,
www.graphpad.com). The data in the graphs are expressed as the mean ± SD. Differences having
* p < 0.05, ** p < 0.01, *** p < 0.001, or **** p < 0.0001 were considered statistically significant.
3. Results
3.1. Characterisation of the Immune Responses induced by HSP90-E6
To examine whether HSP90-E6 induces an antigen (Ag)-specific memory T-cell response, we
analysed Ag-specific IFN-γ, TNF-α, IL-2, IL-4, IL-10, and IL-17 production in the lungs, spleen,
and lymph nodes of mice 4 weeks after the last immunisation and before challenge (Figure 1a,
green arrow). All Ag-specific Th1 cytokines, except IL-4 and IL-10, were significantly induced in
mice immunised with ESAT-6 or HSP90-E6 when compared to mice immunised with BCG alone
(Figure 1b,c). When stimulated with purified protein derivative (PPD) antigen, IFN-γ, TNF-α and
IL-2 production in the lungs, spleen, and lymph nodes of mice immunised with HSP90-E6 was
significantly higher than that in mice immunised with BCG or ESAT-6 (Figure 1b). Notably, upon
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re-stimulation with ESAT-6, not only Th1 cytokines, but also the Th17-related cytokine IL-17 was
significantly produced in all three tissues evaluated in the HSP90-E6 immunised mice, when compared
to the other treatment groups (Figure 1c). These results suggested that HSP90-E6/CIA05-boosting
establishes Th1/Th17-biased immunity.
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vaccination. (a) Experimental design for HSP90-E6 subunit vaccine testing. Mice (n = 12 per group) 
were immunised by BCG injection 12 weeks before subunit vaccination. Three intramuscular injection 
of HSP90-E6/CIA05 were administered (blue arrows) before Mycobacterium tuberculosis (Mtb) HN878 
aerosol challenge (black arrow). Immunological analysis was conducted before (green arrow) and 
after Mtb infection (red arrow). Bacterial counts and histopathology in each group were determined 
at the indicated time points after Mtb infection (red arrow). (b,c) Levels of IFN-γ, TNF-α, IL-2, IL-10, 
IL-4, and IL-17 secreted by lung, spleen, and lymph-node cells from each fully immunised group in 
response to ESAT-6 (2 μg/mL) or purified protein derivative (PPD) (2 μg/mL) stimulation as detected 
by enzyme-linked immunosorbent assay (ELISA). * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to 
BCG-immunised mice. ** p <0.01 and *** p < 0.001 between BCG+ESAT-6- and BCG+HSP90-E6-
immunised mice. 
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Figure 1. Comparative cytokine production profiles in Bacillus Calmette-Guérin (BCG)-, BCG+ESAT-6-,
or BCG+HSP90-E6-vaccinated mice upon antigen (Ag) stimulation four weeks after final vaccination. (a)
Experimental design for HSP90-E6 subunit vaccine testing. Mice (n = 12 per group) were immunised by
BCG injection 12 weeks before subunit vaccination. Three intramuscular injection of HSP90-E6/CIA05
were administered (blue arrows) before Mycobacterium tuberculosis (Mtb) HN878 aerosol challenge
(black arrow). Immunological analysis was conducted before (green arrow) and after Mtb infection
(red arrow). Bacterial counts and histopathology in each group were determined at the indicated
time points after Mtb infection (red arrow). (b,c) Levels of IFN-γ, TNF-α, IL-2, IL-10, IL-4, and IL-17
secreted by lung, spleen, and lymph-node cells from each fully immunised group in response to ESAT-6
(2 µg/mL) or purified protein derivative (PPD) (2 µg/mL) stimulation as detected by enzyme-linked
immunosorbent assay (ELISA). * p < 0.05, ** p < 0.01 and *** p < 0.001 compared to BCG-immunised
mice. ** p <0.01 and *** p < 0.001 between BCG+ESAT-6- and BCG+HSP90-E6-immunised mice.
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3.2. HSP90-E6/CIA05 induces Ag-Specific Multifunctional T-Cells
Although there is no consensus on correlates of protection against TB in TB vaccine development,
recent studies in animal models have suggested the protective contribution of multifunctional T-cells
and a Th17-mediated immune response against Mtb infection [13,28,29,35]. Therefore, we next
assessed the generation of Ag-specific IL-17-, IFN-γ-, TNF-α- and IL-2-producing multifunctional
T-cells upon ex vivo re-stimulation with ESAT-6 after the final immunisation. CD4+ T-cells
collected from the lungs, spleen, and lymph nodes were stained for intracellular cytokines and
subtyped by multi-colour flow cytometry (Supplementary Materials Figure S1). We focused on
multifunctional T-cells producing IL-17 and IFN-γ for comparative analysis. Upon re-stimulation
with ESAT-6 or PPD, HSP90-E6/CIA05 immunisation induced expansion of Ag-specific CD4+CD44+
multifunctional T-cells (IFN-γ+IL-17+TNF-α+IL-2+, IFN-γ+IL-17+IL-2+, IFN-γ+IL-17+TNF-α+, and
IFN-γ+IL-17+ cells) in the lungs, spleen, and lymph nodes to a similar extent as ESAT-6/CIA05
immunisation. These multifunctional T-cells were more strongly expanded in HSP90-E6/CIA05- than in
ESAT-6/CIA05-immunised mice, especially in the spleen (Figure 2, Supplementary Materials Figure S2).
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section. Four weeks after the last immunisation, the mice were sacrificed, and their lung, spleen, and
lymph-node cells collected from the mice were treated with ESAT-6 (2 µg/mL) at 37 ◦C for 12 h in
the presence of GolgiStop. Upon stimulation with ESAT-6, cell counts of Ag-specific, multifunctional
CD4+CD44+ T-cells producing IFN-γ, IL-17 and/or TNF-α and IL-2 in the lung, spleen, and lymph-node
cells from each immunised group were determined by flow cytometry. Gray arc denotes the percentage
of cytokine-positive T-cells (IL-17+IFN-γ+TNF-α+IL-2+-, IL-17+IFN-γ+IL-2+-, IL-17+IFN-γ+TNF-α+-,
and IL-17+IFN-γ+-CD4+CD44+ T-cells). The figure 2+ stands for sum percentages of double-cytokine
positive T-cells (IL-17+IFN-γ+, IL-17+TNF-α+, and IL-17+IL-2+), 3+ stands for triple-cytokine
positive T-cells (IL-17+IFN-γ+IL-2+, IL-17+IFN-γ+TNF-α+ and IL-17+TNF-α+IL-2+), and 4+ stands for
quadruple-cytokine positive T-cells (IL-17+IFN-γ+TNF-α+IL-2+). Data are expressed as the mean ± SD
for five mice from each group. n.s.: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001
compared to BCG-immunised mice. n.s.: not significant, * p < 0.05, ** p < 0.01 between BCG+ESAT-6-
and BCG+HSP90-E6-immunised mice.
3.3. Protective Efficacy of HSP90-E6 Boosting against Hypervirulent Mtb HN878
Given the early protective role of IL-17 and the protective efficacy of HSP90-E6/MPL-DDA
vaccination against Mtb HN878 [10,28], any Ag that can enhance the limited BCG efficacy against
emerging Mtb strains during long-term infection can be regarded a novel vaccine target. In this context,
we evaluated the protective efficacy of HSP90-E6/CIA05 suggested by the immunisation-induced
Ag-specific multifunctionality, including IFN-γ+IL-17+ T-cells (Figures 1 and 2). Mice were
challenged with Mtb HN878 4 weeks after the last immunisation, and the bacterial burden in
and histopathology of the lungs and spleen were evaluated 10 weeks post-infection (Figure 1a). In
HSP90-E6/CIA05-boosted mice, lung inflammation, and lesion size were significantly ameliorated
when compared to the BCG-vaccinated mice or ESAT-6/CIA05-boosted mice group (Figure 3a,b).
Moreover, bacterial burden in the lungs and spleen was significantly lower in HSP90-E6/CIA05-boosted
than in ESAT-6/CIA05-boosted mice (Figure 3c). These results suggested that HSP90-E6 vaccination
can boost the protection induced by BCG.
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were used to compare groups. n.s.: not significant, * p < 0.05, ** p < 0.01, and *** p < 0.001.
3.4. Multifunctional T-Cells and Cytokine Profiles in Mice Immunised with BCG Prime HSP90-E6/CIA05
Boosting after Challenge with Mtb HN878
Based on the immunological contribution of vaccination-induced Th1/Th17-biased immunity
(Figure 1) and the enhanced protection (Figure 3), we next evaluated whether the magnitude and
quality of poly-functionalities upon Ag re-stimulation, represented by IFN-γ+ and IL-17+, could be
sustainably i duced or expanded. At 10 weeks after HN878 challenge, lung cells (Figure 4a) and
splenocytes (Supplementary Materials Figure S3) were stimulated ex vivo with PPD or ESAT-6, a
CD4+ Ag-s ecific T-cells were typed by multi-colo r flow cytometry. In addition, culture supernatants of
Ag re-stimulated lung and s leen cells were analysed by enzyme-linked imm osorbent assay (ELISA)
(Figure 4b). Robust expa sion of Ag-specific CD4+CD44+ multi-functional (IFN-γ+IL-17+TNF-α+IL-2+,
IFN-γ+IL-17+IL-2+, IFN-γ+IL-17+TNF-α+ and IFN-γ+IL-17+) T-cells was observed—especially in lung
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cells—after stimulation with ESAT-6 or PPD in BCG-primed HSP90-E6/CIA05-boosted, compared to
ESAT-6/CIA05-vaccinated mice (Figure 4a). Similar results were obtained in spleen cells stimulated with
ESAT-6 (Supplementary Materials Figure S3). Furthermore, Th1-related IFN-γ, but not Th2-related
cytokines, such as IL-4 and IL-10, was markedly increased upon PPD stimulation of lung and
spleen cells from fusion protein-boosted mice when compared to the corresponding responses in
ESAT-6/CIA05-boosted mice (Figure 4b). Th17-related IL-17 production was higher in lung cells from
HSP90-E6/CIA05-boosted than in those from ESAT-6/CIA05-boosted mice (Figure 4b). Upon ESAT-6
stimulation, protective cytokines in lungs and spleen where more strongly induced in HSP90-E6/CIA05-
than in ESAT-6/CIA05-boosted mice. Interestingly, IL-2 production was significantly up-regulated in
lung cells and splenocytes upon PPD or ESAT-6 re-stimulation, suggesting that increased IL-2 production
contributes to the quality of T-cell responses. These results suggested that HSP90-E6 vaccination can
boost protective Ag-specific multifunctional T-cells, especially CD4+CD44+ IFN-γ+IL-17+ T-cells.
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obtained from the mice were treated with ESAT-6 (2 µg/mL) at 37 ◦C for 12 h in the presence
of GolgiStop. Upon stimulation with the ESAT-6, cell counts of Ag-specific, multifunctional
CD4+CD44+ T-cells producing IFN-γ, IL-17 and/or TNF-α and IL-2 in the spleen and lung cells
in all treatment groups were determined by flow cytometry. Gray arc denotes the percentage of
cytokine-positive T-cells (IL-17+IFN-γ+TNF-α+IL-2+-, IL-17+IFN-γ+IL-2+-, IL-17+IFN-γ+TNF-α+-,
and IL-17+IFN-γ+-CD4+CD44+ T-cells). The figure 2+ stands for sum percentages of double-cytokine
positive T-cells (IL-17+IFN-γ+, IL-17+TNF-α+, and IL-17+IL-2+), 3+ stands for triple-cytokine
positive T-cells (IL-17+IFN-γ+IL-2+, IL-17+IFN-γ+TNF-α+ and IL-17+TNF-α+IL-2+), and 4+ stands for
quadruple-cytokine positive T-cells (IL-17+IFN-γ+TNF-α+IL-2+). Data are the mean ± SD for 6 or 7
mice from each group. (B) Levels of IFN-γ, TNF-α, IL-2, IL-10, IL-4, and IL-17 secreted by lung and
spleen cells in all treatment groups in response to ESAT-6 (2 µg/mL) or PPD (2 µg/mL) stimulation as
detected by ELISA. n.s.: not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 compared
to BCG-immunised mice. n.s.: not significant, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 between
BCG+ESAT-6- and BCG+HSP90-E6-immunised mice.
3.5. Correlates of Protection for Improved BCG Boosting Efficacy of BCG-HSP90-E6/CIA05 in the Lungs
Next, we aimed to identify immunological correlates for the improved BCG-primed protection
conferred by HSP90-E6/CIA05 boosting. Given that the subunit candidate elicited predominantly
CD4+-biased T-cell responses, positive correlates associated with enhanced protection against highly
virulent Mtb infection were analysed based on the experimental set-up in this study. We previously
reported that growth inhibition of Mtb in HSP90-E6/MPL-immunised mice is related with the activation
of CD4+CD44+IFN-γ+TNF-α+IL-2+ multifunctional T-cells [10]. In line herewith, these multifunctional
T-cells were expanded in the lungs of HSP90-E6/CIA05-immunised mice before (Supplementary
Materials Figure S4) and after (Supplementary Materials Figure S5) challenge. To identify protective
biomarkers for clinical or experimental evaluation of TB vaccine candidates, CD4+ T-cell subsets
expressing various combinations of four cytokines were compared among the different treatment
groups. As shown in Figure 5a, the CD4+CD44+IFN-γ+IL-17+ T-cell (R = −0.8641, p < 0.0001)
responses to ESAT-6 in BCG-HSP90-E6/CIA05-vaccinated mice correlated with bacterial loads in both
pre-and post-infections; CD4+CD44+IFN-γ+IL-17+TNF-α+IL-2+ T-cells (R = −0.9082, p < 0.0001),
CD4+CD44+IL-17+ T-cells (R = −0.8183, p < 0.0001), and CD4+CD44+IL-17+IL-2+ T-cells (R = −0.6333,
p = 0.0002) appeared to be significantly correlated only in pre-infected mice, which suggested that these
cell populations could be the key factors correlating with BCG-HSP90-E6/CIA05 vaccination-induced
protection. On the other hand, CD4+CD44+IFN-γ+IL-17+IL-2+ T-cells (R = −0.7133, p < 0.0001) and
CD4+CD44+IFN-γ+TNF-α+IL-2+ T-cells (R = −0.6845, p < 0.0001) showed correlation with bacterial
load only post-infection. However, the CD4+CD44+IFN-γ+ T-cell (R = 0.6789, p < 0.0001) responses
to ESAT-6 correlated negatively with bacterial load post-infection, but not pre-infection (Figure 5b).
No prominent correlation was observed in other multifunctional T-cells (Supplementary Materials
Figures S6 and S7). The correlation results are summarised in Supplementary Materials Table S1 by
ranking. Taken together, these data suggested that Ag-specific IFN-γ+IL-17+ responses are involved in
HSP90-E6/CIA05-mediated BCG boosting effects.
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line with the correlation coefficient. (a) Positive correlation, (b) some relation or negative correlation.
Spearman’s r and P values of the correlations are indicated. White circle: naïve or infection, green
circle: BCG, red circle: BCG+E6, and blue circle: BCG+HSP90-E6.
3.6. Th1- and Th17-Related Responses are Simultaneously induced in DCs and Co-Cultured CD4+ T-Cells
upon Stimulation with HSP90-E6
Recent studies have suggested that IFN-γ/IL-17 responses contribute to protection against Mtb
infection [13,28,36–39]. We previously reported that proinflammatory cytokines such as IFN-γ and
IL-17, which are related to anti-mycobacterial activity, were significantly induced by T-cells activated
by HSP90-matured DCs [10]. Therefore, we next tested whether HSP90-E6-matured DCs produce
cytokines related to Th1/Th17 polarisation. Interestingly, the fusion protein significantly stimulate
the secretion of TNF-α, IL-1β, IL-12p70, and IL-23p19, but not IL-10, which have important roles
in Th1/Th17 differentiation, in DCs, whereas untreate DCs secreted negligible amounts of these
c t i es (Figure 6a). Next, we determined whether HSP90-E6-matured DCs affect cell proliferation.
To evaluate the effect of HSP90-E6 on the i teraction betwee DCs and T-cells, we perf rmed in vitro
-cell proliferation assays of carboxyfluorescein succinimidyl ester (CFSE)-labelled sorted CD4+ T-cells
obtained from vaccinated mice upon co-culture with DCs stimulated with individual vaccine antigens
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for 72 h. T-cells from mice injected with BCG alone were cocultured with PPD-treated DCs. HSP90-E6-,
PPD-, or ESAT-6-treated DCs induced T-cell proliferation primed by immunisation with each Ag to
a significantly greater extent than did untreated DCs (Figure 6b). T-cells activated with PPD, ESAT-6,
or HSP90-E6-treated DCs produced significantly higher levels of cytokines than those activated with
untreated DCs (Figure 6c). The production of IFN-γ, IL-17, and TNF-α was significantly higher in
T-cells co-cultured with HSP90-E6-treated DCs than in T-cells co-cultured with E6- or PPD-treated DCs.
IL-2 production was similarly induced upon co-culture with all Ag-treated DCs. However, T-cells
activated with E6- or HSP90-E6-matured DCs did not significantly produce Th2-related cytokines IL-4
and IL-10, whereas T-cells activated with PPD did (Figure 6c). We next evaluated the differentiation
of CD4+ T-cells using intracellular transcription factor immunostaining. As shown in Figure 6d,
the expression of the Th1/Th17-associated transcription factors T-bet and RoRγt was increased in
proliferating T-cells co-cultured with HSP90-E6-treated DCs, as compared to the levels in T-cells
co-cultured with E6-treated DCs (Figure 6d). Taken together, these results suggested that HSP90-E6 is
capable of simultaneously polarizing T-cells towards Th1 and Th17.
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Figure 6. T-cell proliferation and differentiation induced by HSP90-E6-treated dendritic cells (DCs). (a)
DCs were activated with PPD (2 µg/mL), ESAT-6 (2 µg/mL), or HSP90-E6 (2 µg/mL) for 24 h. TNF-α,
IL-1β, IL-12p70, IL-10, and IL-23p19 levels in the culture medium were measured by ELISA. Data are
the mean ± SD (n = 3). (b) CD4+ T-cells were isolated from the spleens of individually vaccinated mice,
stained with carboxyfluorescein succinimidyl ester (CFSE), and co-cultured with DCs treated with PPD
(2 µg/mL), E6 (2 µg/mL), or HSP90-E6 (2 µg/mL) for 3 days. T-cells alone and T-cells co-cultured
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with untreated DCs served as controls. CD4+ T-cell proliferation was assessed by flow cytometry. (c)
Culture supernatants were harvested after 3 days and TNF-α, IFN-γ, IL-2, IL-4, IL-10, and IL-17A
secretion levels were measured by ELISA. (d) Expression of Th1- and Th17-related transcription factors
was assessed using intracellular staining after 4 days of co-culture with DC:T-cells (CON: Naïve T-cells,
PPD: BCG vaccinated T-cells, E6: ESAT-6/CIA05 immunised T cells, HSP90-E6: HSP90-ESAT-6/CIA05
immunised T cells). Data are the mean ± SD from three independent experiments; * p < 0.05 versus
appropriate controls. n.s.: no significant difference, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001
compared to untreated DCs. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 between ESAT-6-
and HSP90-E6-treated DCs.
3.7. IFN-γ and IL-17 Synergistically Exert Anti-Mycobacterial Activity Via Enhanced Phagolysosomal
Maturation
The involvement of IL-17 in the protection against Mtb infection has been controversial, as
the interaction between Th1 and Th17 cells is not well understood [13,30,40,41]. Th17 responses
reportedly do not inhibit the generation of Th1 cells in vitro, and favour Th1 responses in vivo [41].
Thus, we hypothesised that IL-17 alone does not effectively inhibit Mtb growth within macrophages,
but may act synergistically with IFN-γ. To investigate this hypothesis, Mtb-infected macrophages
were treated with IFN-γ, IL-17 or both. IL-17 alone did not inhibit intracellular Mtb growth, even at
concentrations up to 100 ng/mL, whereas IFN-γ alone significantly inhibited Mtb growth at 1 ng/mL,
with no significant difference between 1 ng/mL and 10 ng/mL of IFN-γ (Supplementary Materials
Figure S8). Interestingly, IFN-γ plus IL-17 at 1 ng/mL each significantly inhibited Mtb growth in
macrophages, when compared to 1 ng/mL IFN-γ (Figure 7a), and IFN-γ plus IL-17 at 5 ng/mL each
significantly inhibited Mtb growth, when compared to 100 ng/mL IFN-γ (Supplementary Materials
Figure S8). Mtb growth was inhibited in a concentration-dependent manner upon treatment with
both cytokines (Supplementary Materials Figure S8). These results suggested that IL-17 synergistically
enhances the anti-mycobacterial activity of IFN-γ.
We previously demonstrated that T-cells activated with HSP90-E6-matured DCs inhibit Mtb
growth in macrophages [10]. Therefore, we further investigated the synergistic effect of both cytokines
on HSP90-E6-mediated anti-mycobacterial activity after inhibition of cytokine signalling by using
neutralizing anti-cytokine antibodies. As expected, Mtb-infected macrophages co-cultured with
T-cells activated by HSP90-E6-matured DCs significantly inhibited intracellular bacterial growth,
when compared to infected macrophages co-cultured with T-cells activated by untreated DCs
(Figure 7b). Pre-treatment with anti-IFN-γ or both anti-IFN-γ and anti-IL-17 completely abrogated
HSP90-E6-mediated Mtb growth inhibition via T-cell activation. There was no difference in inhibitory
activity between anti-IFN-γ and both anti-IFN-γ and anti-IL-17. The anti-IL-17 antibody alone also
showed inhibitory activity, but less than the anti-IFN-γ antibody, indicating that IL-17 synergistically
enhances the antimycobacterial activity of IFN-γ. Next, we evaluated the roles of both cytokines
in Mtb-infected macrophages exposed to supernatants from ESAT-6-re-stimulated lung cells of
HSP90-E6-vaccinated mice before and after challenge. Ag-stimulated culture supernatants significantly
inhibited Mtb growth in macrophages when compared to untreated culture supernatants (Figure 7c),
and these inhibitory effects were abrogated upon addition of anti-IFN-γ and/or anti-IL-17. Supernatants
from ESAT-6-re-stimulated spleen cells of HSP90-E6-vaccinated mice before and after challenge showed
a similar Mtb growth-inhibitory effect, which was also neutralised by anti-IFN-γ and/or anti-IL-17
(Supplementary Materials Figure S9). However, supernatants from ESAT-6-re-stimulated spleen and
lung cells collected from BCG-vaccinated naïve mice before Mtb challenge did not inhibit Mtb growth
in macrophages, and supernatants from ESAT-6-re-stimulated spleen and lung cells of E6-boosted
mice showed a limited inhibitory effect (Supplementary Materials Figure S10). Culture supernatants
from the spleen and lung cells of BCG-vaccinated mice after Mtb challenge did not inhibit Mtb growth
in macrophages and culture supernatants from the lung, but not in the spleen cells of E6-boosted
mice, which showed a limited inhibitory effect (Supplementary Materials Figures S11 and S12). These
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results suggested that effector T-cells with antimycobacterial activity are effectively expanded in
HSP90-E6-boosted mice.
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Next, we examined whether IFN-γ and IL-17 could affect phagosome-lysosome fusion, which is
the Mtb-killing mechanism of macrophages. As shown in Figure 8a, IL-17 alone did not induce
phagosome maturation, but it did significantly enhance IFN-γ-mediated colocalisation of Mtb
with the lysosomal marker LAMP1. Mtb–LAMP1 colocalisation was more strongly induced upon
co-treatment with IFN-γ and IL-17 (1 ng/mL each) than after treatment with IFN-γ (1 ng/mL) alone
(Figure 8a), and the level of colocalisation was comparable to that after treatment with 100 ng/mL
IFN-γ (Supplementary Materials Figure S13). IFN-γ and IL-17 did not show a synergistic effect
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on IFN-γR1 expression in Mtb-infected macrophages (Supplementary Materials Figure S14), nor
on reactive oxygen species (ROS) production, which was increased by IFN-γ or IL-17 treatment
(Supplementary Materials Figure S15a). As expected, IFN-γ, but not IL-17 induced nitric oxide (NO)
production in Mtb-infected macrophages, and IFN-γ-mediated NO production was decreased upon
IL-17 treatment (Supplementary Materials Figure S15b). Supernatants from ESAT-6-re-stimulated
lung cells of HSP90-E6-vaccinated mice significantly enhanced Mtb–LAMP1 colocalisation, which was
decreased upon treatment with anti-IFN-γ or anti-IL-17 (Figure 8b). These data suggested that antigens
capable of simultaneously inducing Th1 and Th17 responses may have strong TB vaccine potential.
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for 3 days. Intracellular Mtb growth in the BMDMs was determined after 3 days. Data are the mean ± 
SD (n = 3); * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. n.s.: no significant difference. 
 
Figure 8. IFN-γ and IL-17 synergistically inhibit intracellular bacterial growth via phagosome-
lysosome fusion. BMDMs were infected with Mtb-RFP (MOI = 1) for 4 h, washed, incubated 
with/without IFN-γ, IL-17, or IFN-γ/IL-17 (1 ng/mL) (a) or with supernatants of ESAT-6-re-stimulated 
in HSP90-E6-vaccinated lung cells with/without anti-IFN-γ or anti-IL-17 (b) for 72 h, fixed with 4% 
paraformaldehyde, and immunolabeled with anti-LAMP1 antibody and Alexa 488-conjugated goat 
anti-rabbit or anti-rat IgG (green). Nuclei were counterstained with DAPI (chromosome counterstain, 
4′,6-diamidino-2-phenylindole, blue). The cells were analysed by laser-scanning confocal microscopy. 
Scale bar, 10 μm. Quantification of Mtb–LAMP1 colocalisation is shown in the bar graph. Data are the 
mean ± SD of 50–100 cells per experiment (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001 
versus infection only control (CON) or for differences between treatments. n.s., no significant 
difference. 
4. Discussion 
Figure 8. IFN-γ and IL-17 synergistically inhibit intracellular bacterial growth via phagosome-lysosome
fusion. BMDMs were infected with Mtb-RFP (MOI = 1) for 4 h, washed, incubated with/without
IFN-γ, IL-17, or IFN-γ/IL-17 (1 ng/mL) (a) or with supernatants of ESAT-6-re-stimulated in
HSP90-E6-vaccinated lung cells with/without anti-IFN-γ or anti-IL-17 (b) for 72 h, fixed with 4%
paraformaldehyde, and immunolabeled with anti-LAMP1 antibody and Alexa 488-conjugated goat
anti-rabbit or anti-rat IgG (green). Nuclei were counterstained with DAPI (chromosome counterstain,
4′,6-diamidino-2-phenylindole, blue). The cells were analysed by laser-scanning confocal microscopy.
Scale bar, 10 µm. Quantification of Mtb–LAMP1 colocalisation is shown in the bar graph. Data
are the mean ± SD of 50–100 cells per experiment (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001 and
**** p < 0.0001 versus infection only control (CON) or for differences between treatments. n.s., no
significant difference.
4. Discussion
The present study revealed that the TB vaccine candidate HSP90-E6, given as a BCG-prime boost
regimen, confers superior, long-term protection against hypervirulent Mtb HN878 infection when
compared to BCG or BCG-E6 alone. Further, elevated E6-specific CD4+ IFN-γ+IL-17+ T-cells pre- and
post-infection positively correlated with protection against Mtb.
There clearly is an urgent, unmet need for new anti-TB vaccines, and heterologous prime-boost
vaccination appears to be a promising strategy. However, despite increased research efforts on this
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approach in the last two decades, clinical progress has been limited, due to insufficient understandings
on protective immune response, targeting antigens, and scheme of boosting. A number of fusion
protein-based subunit vaccines are being tested as boosters to BCG. We previously demonstrated
that HSP90-E6 formulated with MPL/DDA significantly reduced the bacterial load in mouse lungs
after challenge with HN878 [10], but we did not identify an immunologic correlate of protection
for this fusion vaccine. Here, we report that HSP90-E6 formulated with CIA05/DDA prolongs
BCG-primed boosting and that its protective effect is related to enhancement of Ag-specific-IFN-γ+IL-17+
multifunctional T-cells.
The primary rationale for the development of TB vaccines designed to elicit Th1-cell-based
immunity is based on evidence from various animal models that a strong IFN-γ-mediated Th1 immune
response is the primary protective mechanism of anti-TB immunity [19,35,42–45]. However, an IFN-γ
response is not an optimal correlate of protection [16–18], and an IFN-γ response alone is not sufficient
to control Mtb infection [46]. Our data suggest that the CD4+ T-cell populations that mediate immunity
to TB are likely not solely mediated by IFN-γ-producing Th1 cells, but also by cells whose effector
function is independent of IFN-γ [47,48]. A previous study demonstrated that antigens that do not
elicit Th1 responses uniformly fail to protect against Mtb, but not all proteins that induce robust Th1
responses after vaccination provide considerable protection [49]. In addition, Th17 cells reportedly
also contribute to protective TB immunity in mice [28,29,50], cynomolgus macaques [51], and rhesus
macaques [52]. Although the role of Th17 cells in human patients appears ambiguous [41,53,54], early
Th17 responses are suppressed in progressors as compared to Mtb-infected, healthy controls [55].
Therefore, we analysed Ag-specific T-cell responses to identify immunological correlates for the superior
BCG-primed HSP90-E6 booster vaccination. Notably, BCG-primed HSP90-E6 booster vaccination
simultaneously elicited Th1/Th17-biased immune responses after the last immunisation, especially upon
ESAT-6 re-stimulation of the lung and spleen cells, when compared to BCG-primed ESAT-6-boosted
vaccination (Figure 1). In addition, BCG boost with HSP90-E6/CIA05 induced a significant increase in
the number of Ag-specific CD4+CD44+IL-17+ T-cells co-producing three or two effector cytokines after
in vitro stimulation with ESAT-6 in the spleen cells (Figure 2), but not the lymph-node and lung cells,
which was expected, considering that adjuvanted antigens were injected intramuscularly. We infer
that ready-to-be-expanded IFN-γ/IL-17-producing multifunctional CD4+ T-cells exist, and that their
Ag-specific expansion induced by HSP90-E6 boosting possibly contributes to the enhanced protection
against Mtb infection.
Based on these results, we evaluated the protective effect of BCG-prime HSP90-E6/CIA05
vaccination against the hypervirulent HN878 strain in a mouse model. HSP90-E6/CIA05 vaccination
markedly enhanced the protective efficacy of BCG at 10 weeks post-infection, as indicated by reduced
bacterial loads and smaller inflamed lesions (Figure 3). Furthermore, BCG-prime HSP90-E6 vaccination
induced an exclusive quadruple cytokine-positive population, expressing both IL-17 and IFN-γ in
addition to IL-2 and TNF-α. The ESAT-6-specific IL-17-, IFN-γ-, TNF-α-, and IL-2-producing CD4+
T-cell population in the lungs and spleen was considerably larger than that in BCG-immunised and
BCG-primed ESAT-6-boosted mice, and Ag-specific CD4+CD44+ T-cells in the lungs were expanded
when compared to pre-infection numbers (Figure 4). Pre-infection expansion of IFN-γ/IL-17-producing
cells in the lungs was inversely correlated with bacterial burden (R = −0.8641, p < 0.0001), but there
was no significant correlation between IFN-γ-producing cell responses and lung bacterial burden (R =
−0.0679, p = 0.726). Notably, the expansion of Ag-specific CD4+IFN-γ+IL-17+ T-cells was identified as
a correlate of protection after Mtb challenge (R = −0.7703, p < 0.0001), indicating that these cells are an
exclusive feature of BCG-primed HSP90-E6 vaccination. Given that Ag-specific IFN-γ responses were
similarly induced in all groups of immunised mice, an IFN-γ response alone is insufficient to control
Mtb infection (R = 0.6789, p < 0.0001), especially in the absence of IL-17 contribution (Figure 5).
It was difficult to detect differences between the groups when multifunctional T-cell responses were
presented as percentages of the parental populations; therefore, we used actual cell counts to evaluate
T-cell responsiveness against Ag and how many Ag-responding T-cells existed in the Mtb-infected
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tissues. Upon vaccination but prior to infection, CD4+CD44+ T-cell numbers generally increased in
all organs, when compared to the numbers in naïve mice. Additionally, splenic CD4+CD44+ T-cells
displayed increased infiltration of cells capable of producing cytokines in response to Ag stimulation in
both boosted groups, which may be because of the route of Ag immunisation. Further, multifunctional
T-cells were more highly expanded in HSP90-E6-than in ESAT-6-boosted mice (Figure 2). Upon
infection, the expansion of PPD-/ESAT-6-specific multifunctional T-cells in the lungs and ESAT-6-specific
multifunctional T-cells in the spleen were more obvious in HSP90-E6- than in ESAT-6-boosted mice,
which is linked to protective efficacy of HSP90-E6, which outperforms BCG and BCG-prime ESAT-6
vaccination (Figures 3 and 4, and Supplementary Materials Figure S3).
In vitro, HSP90-E6 also significantly induced DCs possessing a Th1/Th17-polarizing phenotype,
characterised by IL-1β, IL-12p70, and IL-23p19 production, as compared to ESAT-6 alone. Moreover,
IFN-γ and IL-17 production in T-cells from individually vaccinated mice was markedly increased
upon co-culture with HSP90-E6- versus ESAT-6-treated DCs, and was accompanied with enhanced
T-cell proliferation (Figure 6), demonstrating that HSP90-E6 is capable of inducing Th1/Th17-biased
responses mediated by optimal DC activation. Most importantly, IFN-γ and IL-17 clearly synergistically
contributed to intracellular bacterial growth inhibition in Mtb-infected macrophages through enhanced
phagolysosomal fusion (Figures 7 and 8), whereas ROS, NO, and up-regulation of IFN-γR1 were not
involved in the synergistic effect (Supplementary Materials Figures S14 and S15). Thus, we identified
an unappreciated role for IFN-γ/IL-17 synergism in inducing anti-bacterial phagosomal activity for
the control of Mtb infection in the host, in addition to the existing paradigm that IL-17 rapidly promotes
cell recruitment, and thereby contributes to early granuloma formation in infection sites.
In summary, our study revealed that HSP90-E6/CIA05 vaccine exerts a durable BCG-boosting effect
against hypervirulent HN878 Mtb in mice via expansion of IFN-γ/IL-17-producing cells in the lungs.
The number of IFN-γ-producing T-cells in the lungs was significantly increased in only infection
group, but decreased in HSP90-E6/CIA05-immunised group. This suggests that IFN-γ-producing
T-cells are necessary, but not sufficient for TB defence, and, more importantly, that an increase in
the number of cells that produce both IFN-γ and IL-17 is important for protection. Further, our
results indicate that the presence of both IFN-γ and IL-17 in the lungs upon Mtb challenge may be an
essential immunological signature of balanced inflammation and protection. The immune signatures
associated with superior BCG-primed HSP90-E6 booster vaccination provide important leads for
further investigation of the direct role of IL-17 in protection against TB and a novel strategy to improve
BCG-booster vaccines. Thus, IFN-γ/IL-17-producing multifunctional CD4+ T-cells are determinants of
protective efficacy of TB subunit vaccines, and HSP90-E6/CIA05 is an excellent TB vaccine candidate
that effectively induces such a response.
5. Conclusions
Collectively, out study demonstrated that IFN-γ-producing T-cells are necessary, but not sufficient
for TB defense, and, more importantly, that an increased in the number of cells that produce both IFN-γ
and IL-17 is essential for protection. This protective immune determinant related with BCG-primed
HSP90-E6 booster vaccination will pave the way for further investigation of a novel strategy to improve
BCG-booster vaccines.
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